Ps100 bÊta and mia, interests in the biological follow-up of cutaneous melanoma
- At: 2007 FIP Congress in Beijing (China)
- Type: Poster
- By: POGGI, Bernard (Depatment of Biochemistry HOTEL DIEU, Lyon, France)
- Co-author(s): GELINEAU, M.C. (Depatment of Biochemistry HOTEL DIEU, LYON, France)
THOMAS, L. (Department of Dermatology HOTEL DIEU, LYON, France)
The prognosis of survivals for the cutaneous melanoma at metastatic stages is 2 or 3 % at 5 years. A simple non-invasive biological marker which would identify the high-risk patients at an early stage would improve the follow-up as well as the prognosis. We explored and evaluated the advantage of two markers, Melanoma Inhibiting Activity (MIA) and .. The access to the whole abstract and the presentation file is available to FIP members and to congress participants of that specific congress.